Skip to main content
Premium Trial:

Request an Annual Quote

Laval, Oxford Universities Establish Forest Genomics Consortium

NEW YORK (GenomeWeb) – Université Laval in Quebec City and the University of Oxford have partnered to create an international consortium in forest genomics, regional funding agency Genome Quebec said yesterday.

The consortium will be led by John MacKay, full professor at Université Laval and a professor of forest science at Oxford University, and will address the major scientific challenges involving the productivity and sustainability of both natural and managed forests.

A spokesperson for Genome Quebec told GenomeWeb in an email that the consortium is still in the development stage, and although it has initiated discussions with other partners in Canada and other leading nations in forest genomics, no relationships have been formalized yet.

Given their economic significance, forest resources are a top government priority in Canada, Genome Quebec noted. Genomics technology provides a valuable method of identifying the potential of individual trees and lines of trees, and as such can help address the challenge of forest sustainability, the agency noted.

Specifically, next-generation sequencing will play a large role in scientific projects under the consortium, the spokesperson said.

"NGS technologies can be used to address many different questions related to the challenges that are facing trees and forests, including pests and pathogens, adaptability to environmental change, forest productivity, and bioenergy production from woody biomass," the spokesperson noted.

Many relevant forest genomics projects are already underway in Quebec, including, for instance, some dealing with the spruce budworm, a major threat to forest health and the lumber industry.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.